446 related articles for article (PubMed ID: 29562644)
21. Management of myelofibrosis after ruxolitinib failure.
Bose P; Verstovsek S
Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
[TBL] [Abstract][Full Text] [Related]
22. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
23. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Fuentes-Mattei E; Bayraktar R; Manshouri T; Silva AM; Ivan C; Gulei D; Fabris L; Soares do Amaral N; Mur P; Perez C; Torres-Claudio E; Dragomir MP; Badillo-Perez A; Knutsen E; Narayanan P; Golfman L; Shimizu M; Zhang X; Zhao W; Ho WT; Estecio MR; Bartholomeusz G; Tomuleasa C; Berindan-Neagoe I; Zweidler-McKay PA; Estrov Z; Zhao ZJ; Verstovsek S; Calin GA; Redis RS
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31941838
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
26. JAK inhibitors in the treatment of myelofibrosis.
Levavi H; Hoffman R; Marcellino BK
Clin Adv Hematol Oncol; 2022 Jul; 20(7):456-467. PubMed ID: 35802878
[TBL] [Abstract][Full Text] [Related]
27. Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly.
Kawano N; Saito N; Yoshida S; Kitanaka A; Shide K; Marutsuka K; Ohshima K; Shimoda K
Tohoku J Exp Med; 2022 Feb; 256(2):119-125. PubMed ID: 35173090
[TBL] [Abstract][Full Text] [Related]
28. Hmga2 promotes the development of myelofibrosis in Jak2
Dutta A; Hutchison RE; Mohi G
Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
[TBL] [Abstract][Full Text] [Related]
29. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
Spangrude GJ; Lewandowski D; Martelli F; Marra M; Zingariello M; Sancillo L; Rana RA; Migliaccio AR
Stem Cells; 2016 Jan; 34(1):67-82. PubMed ID: 26439305
[TBL] [Abstract][Full Text] [Related]
30. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
Morsia E; Gangat N
Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
[No Abstract] [Full Text] [Related]
31. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
32. Modern management of splenomegaly in patients with myelofibrosis.
Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
[TBL] [Abstract][Full Text] [Related]
33. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y
Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182
[TBL] [Abstract][Full Text] [Related]
34. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
35. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
Tremblay D; Mascarenhas J
Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Zingariello M; Martelli F; Ciaffoni F; Masiello F; Ghinassi B; D'Amore E; Massa M; Barosi G; Sancillo L; Li X; Goldberg JD; Rana RA; Migliaccio AR
Blood; 2013 Apr; 121(17):3345-63. PubMed ID: 23462118
[TBL] [Abstract][Full Text] [Related]
37. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
38. Beyond JAK inhibitor therapy in myelofibrosis.
Odenike O
Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
[TBL] [Abstract][Full Text] [Related]
39. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.
Gill H; Leung GMK; Kwong YL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):667-675. PubMed ID: 38066870
[TBL] [Abstract][Full Text] [Related]
40. Low-dose ruxolitinib shows effective in treating myelofibrosis.
Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
